Literature DB >> 15165921

Effect of pravastatin on myocardial perfusion after percutaneous transluminal coronary angioplasty.

Olivia Manfrini1, Carmine Pizzi, GianLuigi Morgagni, Fiorella Fontana, Raffaele Bugiardini.   

Abstract

We studied the effect of pravastatin on coronary perfusion after percutaneous transluminal coronary angioplasty. An exercise test performed within 2 weeks after percutaneous transluminal coronary angioplasty induced reversible perfusion defects in 66% of patients taking pravastatin and 64% of those taking placebo. At follow-up, the exercise test still induced reversible perfusion defects in 3% of patients taking pravastatin and 29% of those taking placebo.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15165921     DOI： 10.1016/j.amjcard.2004.02.037

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  9 in total

1.  Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424.

Authors:  Leslee J Shaw; Gary V Heller; Paul Casperson; Romalisa Miranda-Peats; Piotr Slomka; John Friedman; Sean W Hayes; Ronald Schwartz; William S Weintraub; David J Maron; Marcin Dada; Spencer King; Koon Teo; Pamela Hartigan; William E Boden; Robert A O'Rourke; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2006-09       Impact factor: 5.952

2.  Angina pectoris and physiological coronarographic findings.

Authors:  Mehmed Kulić; Elnur Tahirović; Zina Lazović
Journal:  Bosn J Basic Med Sci       Date:  2009-08       Impact factor: 3.363

Review 3.  Sex-Specific Disparities in Risk Factors for Coronary Heart Disease.

Authors:  Stacey E Rosen; Sonia Henry; Rachel Bond; Camille Pearte; Jennifer H Mieres
Journal:  Curr Atheroscler Rep       Date:  2015-08       Impact factor: 5.113

Review 4.  ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on 'coronary microvascular dysfunction in cardiovascular disease'.

Authors:  Teresa Padro; Olivia Manfrini; Raffaele Bugiardini; John Canty; Edina Cenko; Giuseppe De Luca; Dirk J Duncker; Etto C Eringa; Akos Koller; Dimitris Tousoulis; Danijela Trifunovic; Marija Vavlukis; Cor de Wit; Lina Badimon
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 10.787

Review 5.  Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management.

Authors:  R Preston Mason
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  Women and ischemic heart disease: evolving knowledge.

Authors:  Leslee J Shaw; Raffaelle Bugiardini; C Noel Bairey Merz
Journal:  J Am Coll Cardiol       Date:  2009-10-20       Impact factor: 24.094

Review 7.  Women and Ischemic Heart Disease: Recognition, Diagnosis and Management.

Authors:  Seong-Mi Park; C Noel Bairey Merz
Journal:  Korean Circ J       Date:  2016-07-21       Impact factor: 3.243

8.  Effect of statins on coronary blood flow after percutaneous coronary intervention in patients with stable coronary artery disease.

Authors:  L Cerit; H Duygu; K Gulsen; A Gunsel
Journal:  Neth Heart J       Date:  2017-04       Impact factor: 2.380

9.  Incidence, Predictors, and Prognosis of Coronary Slow-Flow and No-Reflow Phenomenon in Patients with Chronic Total Occlusion Who Underwent Percutaneous Coronary Intervention.

Authors:  Yong Wang; Hong-Wei Zhao; Cheng-Fu Wang; Xiao-Jiao Zhang; Jie Tao; Chun-Sheng Cui; Qing-Kun Meng; Yu Zhu; De-Feng Luo; Ai-Jie Hou; Bo Luan
Journal:  Ther Clin Risk Manag       Date:  2020-02-18       Impact factor: 2.423
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.